Prefrontal and hippocampal microstructural gray matter following cognitive training under moderate hypoxia in mood disorders: a randomized controlled trial

BackgroundCognitive impairment persists during partial or full remission in 50–70% of individuals with mood disorders and impacts daily functioning and clinical prognosis. Preclinical evidence suggests that extended exposure to moderate hypoxia, combined with motor-cognitive learning, may elevate neuroplasticity and improve cognition. In these individuals with remitted mood disorders, we found that cognitive training under repeated moderate normobaric hypoxia improved executive function, and here investigate neurobiological mechanisms.MethodsParticipants with major depressive disorder (MDD) or bipolar disorder (BD) in partial or full remission were randomized to 3 weeks of 3.5-h daily normobaric hypoxia (12% O2) combined with cognitive training five to 6 days per week or treatment-as-usual (TAU). Participants were assessed with cognitive tests and diffusion-weighted MRI at baseline and 1 month after treatment completion (week 8) as part of the ALTIBRAIN trial (ClinicalTrials.gov: NCT06121206). Prefrontal and hippocampal gray matter microstructure were modelled with Neurite Orientation Dispersion and Density Imaging (NODDI).ResultsFifty-seven participants (mean age 39 years, SD: 13, 70% female) with baseline MRI data were included. No significant effects of hypoxia-cognition training vs. TAU on neurite density index (NDI) or orientation dispersion index (ODI) were observed in either the prefrontal cortex or hippocampus (all p-FDR ≥ 0.832). No significant associations were observed between microstructural changes and changes in cognitive function in either region (all p-FDR ≥ 0.721). At baseline, microstructure in both regions was not associated with executive function or global cognition (all p > 0.40).ConclusionThe absence of detectable microstructural changes, despite selective improvements in executive function, indicates that NODDI-derived metrics did not capture structural correlates of the cognitive response to hypoxia-cognition training. Whether this reflects functional neural mechanisms, measurement insensitivity, or the timing of the single follow-up assessment remains to be determined. Future studies should incorporate multiple imaging time points to capture the dynamic trajectories of putative microstructural brain changes.

Personalized audiovisual gamma stimulation enhances neural connectivity and entrainment beyond fixed 40 Hz protocols

BackgroundConventional 40 Hz gamma stimulation is applied across individuals, potentially overlooking inter-individual neural variability.ObjectiveThis study evaluated conversation gamma frequency (CGF)–a personalized gamma frequency derived from task engagement–against the fixed 40 Hz and individual gamma frequency (IGF) derived from auditory responses.MethodsIn Experiment 1, gamma center frequencies were measured under resting, reading, and conversation conditions. In Experiment 2, EEG was used to compare neural entrainment effects across CGF, 40 Hz, and IGF conditions.ResultsConversation gamma frequency stimulation induced stronger neural activation and functional connectivity in the frontal, temporal, and parietal cortices compared to 40 Hz or IGF. Theta-gamma coupling analysis revealed significantly increased phase synchronization under CGF compared to 40 Hz with enhanced connectivity. However, entrainment declined as the frequency difference between CGF, and 40 Hz increased, emphasizing the limitation of fixed-frequency stimulation.ConclusionThese findings provide EEG-based mechanistic evidence that individualized gamma stimulation may represent a hypothesis-generating strategy for future neurorehabilitation research in aging and neurodegenerative conditions.
<![CDATA[Explore today’s narcolepsy care: wake-promoting meds, oxybates for cataplexy, and pitolisant’s histamine boost—plus sleep habits that matter.]]>
<![CDATA[Explore glutamate-based depression treatments—esketamine and dextromethorphan-bupropion—boost synaptogenesis and deliver fast relief when monoamines fail.]]>
<![CDATA[Explore today’s narcolepsy care: from sleep hygiene to stimulants, oxybates, and pitolisant—targeting sleepiness and cataplexy.]]>
<![CDATA[Why settle for “less bad”? Clinicians urge aggressive depression care aimed at true remission, balancing side effects and patient priorities.]]>